Indication
Treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.
Medicine details
- Medicine name:
- secukinumab (Cosentyx)
- SMC ID:
- SMC2592
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC